- Due Diligence
- Industrial Designs
- IP for Start-Up & Early Stage Companies
- Patent Prosecution
- Strategic Counselling, Opinions, & Intellectual Property Portfolio Management
Kazim Agha is a patent agent at Ridout & Maybee LLP in the firm’s Toronto office. His practice focuses in the areas of pharmaceuticals, chemistry, biotechnology, clean technology and mechanical devices. It includes the drafting and prosecution of patent applications, providing patentability, validity, infringement and freedom to operate opinions, and assisting members of the Pharmaceutical Group with matters including NOA preparation and NOC litigation support. In addition, he has prepared and prosecuted patent applications in a variety of other fields such as biomedical devices and nanotechnology.
Kazim is an associate editor of the Canadian Patent Reporter (CPR), and writes and presents on intellectual property matters, including patents and IP strategy.
Prior to his legal career, Kazim was a senior research chemist at a major chemical company where he was responsible for oligonucleotide and other active pharmaceutical ingredient (API) projects from R&D to manufacturing, including process validation and pre-approval inspection (PAI) preparation.
During his studies, Kazim was a National Sciences and Engineering Research Council of Canada (NSERC) Scholar, a Fonds de recherché sur la nature et les technologies (FCAR) Scholar, received the T. Sterry Hunt Award and the best presentation award from the Canadian Society for Chemistry at the 2001 conference; and was President of the Chemistry Graduate Student Society.
- B.Sc. (Honours Chemistry), Dalhousie University (1997)
- Ph.D. (Chemistry), McGill University (2003)
- Project Management Certificate, Grant MacEwan College (2004)
- Registered Patent Agent, Canada (2008)
- Intellectual Property Institute of Canada – IPIC (Associate)
- Chemical Institute of Canada – CIC
- Canadian Society for Chemistry – CSC (Director, Local Sections)
Heller D. & Agha, K. “Deep into the Genome; A Roundtable Discussion on IP, Patenting, and Personalized Medicine”
BioBusiness, pp. 10-12, July/August 2012.